FDA Looks To Strengthen, Speed Drug Reviews With Flow Of Quality Data
New Approach Would Overcome Legacy Burden Of ‘Electronic Paper’
Executive Summary
Lift the burden of paper on drug quality reviews and the pace of innovation is no longer a problem for structural engineers or couriers – or even print or electronic document rooms. The focus at the US FDA is now on enabling direct transmission and analysis of critical quality data.
You may also be interested in...
US FDA Expands KASA Platform To Probe API Synthesis, Conduct NDA Quality Reviews
Agency builds on success with last year’s KASA-based ANDA quality reviews to widen and deepen the software tool’s functionality, says CDER OPQ leadership. CMC assessors are adapting quickly to a platform that could soon alert them to issues like possible genotoxic impurity formation during API synthesis.
NDAs, BLAs To Start Getting KASA Quality Risk Assessments After Successful Pilot With ANDAs
Internal review system reduces US FDA’s administrative work for OPQ risk assessments; agency’s standards will not change, and sponsors will not need to modify applications. Advisory committee endorses expansion, which will roll out to different application types over several years.
US FDA Drops Plan To Simplify Pharmaceutical Plant Reporting
Industry complained draft guidance would have made manufacturing establishment information harder to report, not easier.